Advaxis, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with OS Therapies LLC; Amgen Inc.; Especificos Stendhal SA de CV; Merck & Co., Inc.; MedImmune/AstraZeneca; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone609-452-9813
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$6.06 million
Profitability
Miscellaneous
Employees58
Next Earnings Date6/6/2019 (Estimated)
OptionableOptionable
Advaxis (NASDAQ:ADXS) Frequently Asked Questions
What is Advaxis' stock symbol?
Advaxis trades on the NASDAQ under the ticker symbol "ADXS."
How were Advaxis' earnings last quarter?
Advaxis, Inc. (NASDAQ:ADXS) issued its quarterly earnings data on Tuesday, March, 12th. The biotechnology company reported $0.18 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.25) by $0.43. The biotechnology company earned $19.69 million during the quarter. Advaxis had a negative net margin of 140.12% and a negative return on equity of 101.51%. View Advaxis' Earnings History.
When is Advaxis' next earnings date?
What price target have analysts set for ADXS?
2 Wall Street analysts have issued 1-year price targets for Advaxis' shares. Their forecasts range from $2.00 to $4.00. On average, they anticipate Advaxis' stock price to reach $3.00 in the next twelve months. This suggests that the stock has a possible downside of 9.4%. View Analyst Price Targets for Advaxis.
What is the consensus analysts' recommendation for Advaxis?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advaxis in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Advaxis.
What are Wall Street analysts saying about Advaxis stock?
Here are some recent quotes from research analysts about Advaxis stock:
- 1. According to Zacks Investment Research, "Advaxis, Inc. is a development stage biotechnology company focused on developing safe and effective cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania which secretes a protein sequence containing a tumor-specific antigen. The Company believes this vaccine technology is capable of stimulating the body's immune system to process and recognize the antigen as if it were foreign, generating an immune response able to attack the cancer. It also considers this to be a broadly enabling platform technology that can be applied to the treatment of many types of cancers, infectious diseases and auto-immune disorders. The Company's products in development include Lovaxin C and Lovaxin B, Lovaxin P. " (2/20/2019)
- 2. HC Wainwright analysts commented, "We base our $20 price target on probability-adjusted revenue forecasts for avacopan in AAV and C3G. We use the net present value of our revenue forecast through 2028, apply a 30% probability of success (POS) for avacopan in AAV, a 25% POS for avacopan in C3G, a 3x price/sales multiple, and our estimated fully diluted year- end 2018 net cash of $2.17/share to arrive at our price target. Our P/S multiple of 3x is in-line with ChemoCentryx’s peers that range between 2-5x. We use a 25% discount rate for the pipeline, which includes CCX140, CCX872 and avacopan for HS, as it is above the marketed products discount rate due to development risks but within the typical range of 15-25% for products in development. We project revenues of $72M for avacopan in AAV in 2021, growing to $1.4B in 2028. For avacopan in C3G, we estimate revenues of $10M in 2024, increasing to $124M in 2028." (6/8/2018)
Has Advaxis been receiving favorable news coverage?
Media coverage about ADXS stock has been trending positive on Saturday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Advaxis earned a media sentiment score of 2.6 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an impact on the stock's share price in the next several days.
Who are some of Advaxis' key competitors?
Some companies that are related to Advaxis include Entasis Therapeutics (ETTX), Medicure (MCUJF), Neurotrope (NTRP), Aravive (ARAV), Oramed Pharmaceuticals (ORMP), AEterna Zentaris (AEZS), Ovid Therapeutics (OVID), Pharmaxis (PXSLY), Alimera Sciences (ALIM), Proteostasis Therapeutics (PTI), Vaccinex (VCNX), Aquinox Pharmaceuticals (AQXP), Sienna Biopharmaceuticals (SNNA), vTv Therapeutics (VTVT) and Agile Therapeutics (AGRX).
What other stocks do shareholders of Advaxis own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Advaxis investors own include Madrigal Pharmaceuticals (MDGL), Inovio Pharmaceuticals (INO), Vistagen Therapeutics (VTGN), Merck & Co., Inc. (MRK), Celgene (CELG), Highpower International (HPJ), BIOLINERX LTD/S (BLRX), Anavex Life Sciences (AVXL), Novavax (NVAX) and Synergy Pharmaceuticals (SGYP).
Who are Advaxis' key executives?
Advaxis' management team includes the folowing people:
- Mr. Kenneth A. Berlin J.D., Pres, CEO & Director (Age 55)
- Ms. Molly Henderson CPA, CPA, MBA, Exec. VP, CFO & Corp. Sec. (Age 48)
- Dr. Robert G. Petit, Exec. VP & Chief Scientific Officer (Age 59)
- Mr. Anthony A. Lombardo, Exec. Officer (Age 70)
- Dr. Andres A. Gutierrez, Exec. VP & Chief Medical Officer (Age 58)
Who are Advaxis' major shareholders?
Advaxis' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.29%). Company insiders that own Advaxis stock include Adage Capital Partners Gp, LL, Anthony A Lombardo, Robert Petit, Roni Appel and Sara Bonstein. View Institutional Ownership Trends for Advaxis.
Which major investors are selling Advaxis stock?
How do I buy shares of Advaxis?
Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Advaxis' stock price today?
One share of ADXS stock can currently be purchased for approximately $3.31.
How big of a company is Advaxis?
Advaxis has a market capitalization of $18.23 million and generates $6.06 million in revenue each year. The biotechnology company earns $-66,510,000.00 in net income (profit) each year or ($19.34) on an earnings per share basis. Advaxis employs 58 workers across the globe.
What is Advaxis' official website?
How can I contact Advaxis?
Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected]
MarketBeat Community Rating for Advaxis (NASDAQ ADXS)
MarketBeat's community ratings are surveys of what our community members think about Advaxis and other stocks. Vote "Outperform" if you believe ADXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
